FDAnews
www.fdanews.com/articles/84859-transition-therapeutics-to-acquire-outstanding-shares-of-alzheimer-s-disease-focused-ellipsis-neurotherapeutics-inc

TRANSITION THERAPEUTICS TO ACQUIRE OUTSTANDING SHARES OF ALZHEIMER'S DISEASE FOCUSED ELLIPSIS NEUROTHERAPEUTICS INC.

February 27, 2006

Transition Therapeutics Inc., announced the signing of a Share Purchase Agreement ("Purchase Agreement") with the directors of Ellipsis Neurotherapeutics Inc. ("ENI") pursuant to which Transition will offer to acquire all the remaining outstanding shares of ENI. The key asset in this transaction is ENI's lead molecule AZD-103, a disease modifying agent with the potential to both reduce disease progression and improve symptoms such as cognitive function.
CNW Group